Huaren Pharmaceutical released its 2026 interim report. During the reporting period, the company's total operating revenue was 605 million yuan, down 3.02% year-on-year. Net profit attributable to the parent company was 28.5424 million yuan, down 23.55% year-on-year. Net cash inflow from operating activities was 75.0744 million yuan, a sharp year-on-year decline of 55.80%. The company's asset-liability ratio was 65.83%, up 7.09 percentage points from the same period last year. Gross margin was 32.63%, down 5.11 percentage points year-on-year. ROE was 3.29%, up 0.50 percentage points year-on-year. Diluted earnings per share were 0.02 yuan, down 23.73% year-on-year. Total asset turnover was 0.22 times, up 21.91% year-on-year, marking a second consecutive year of growth. Inventory turnover was 1.69 times, up 30.17% year-on-year. The company had 38,200 shareholders, and the top ten shareholders held 38.76% of the total share capital.
Huaren Pharmaceutical Co LtdNet profit down 23.55%, revenue down, cash flow down sharply, and margins weakened.
